The skin is the largest organ of the body that fulfills multiple essential tasks. It forms the boundary between the inside and outside. It protects against mechanical and chemical threats, it provides innate and adaptive immune defenses, it enables thermoregulation and vitamin D production and it acts as the sensory organ of touch. Skin diseases are a significant cause of global disease burden, affecting millions of people worldwide. There are more than 3000 known diseases of the skin. Aging, environmental and genetic factors and trauma can result in the development of a diverse set of skin diseases. Metadichol a nano formulation of long-chain lipid alcohols derived from food it is an inverse agonist of vitamin D receptor (VDR), aryl hydrocarbon receptor (AHR), and ROR gamma (RORC) that could have beneficial effects on skin diseases. We now present case studies of patients with various skin disease shows Metadichol is an inverse agonist of these named nuclear receptors thus modulating Th1 pathway towards a TH2 and Th 17 and IL 17 and IL22 and also being a TNF alpha inhibitor can modulate IL23 thus blocking the major pathways that exacerbate many skin diseases. Metadichol is the first molecule to successfully navigate around the problems involved with promiscuous ligands and targets. It fulfills the goals of the emerging field of polypharmacology i.e., a single drug is able to bind to multiple targets beyond the one drug, one target philosophy. We show how Metadichol is an innovative treatment or treating multiple skin diseases like eczema, acne, diabetic wounds and viral and bacterial infection and also improving skin texture. Metadichol® is a safe non-toxic low cost solution and is an alternative to numerous clinical candidates in combating over 3000 skin diseases.

Recent Publications


3. Raghavan P R (2017); Metadichol® and vitamin C increase in vivo, an open-label study. Vitam Miner 6:163.

Biography

Palayakotai Raghavan, the CEO of Nanorx INC. He has completed his PhD in Organic Chemistry at Oregon State University in 1979 and MS in Chemistry at IIT Mumbai, India in 1972. He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 25 US and international patents and other 15 pending patent applications.